Business News • PR NewsWire • Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles

Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles

Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles

NEW HAVEN, Conn., April 19, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that it will hold an investor event concurrently with the 2018 American Academy of Neurology (AAN) Annual Meeting in Los Angeles, from 6:00 p.m. to 7:30 p.m. PT on...

View More : https://www.prnewswire.com/news-releases/biohaven-pharmaceuticals-announces-additional-phase-3-rimegepant-data-to-be-rel...

Releted News by prnewswire

Noo Nectar liquid nootropic stack with more than 20 nutrient-rich ingredients expanding distribution in U.S.

Les attaques de botnets : une cyber-menace persistante

INFOkontor : faire du transport électrique efficace une réalité

Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles

Philips showcases dedicated radiation oncology workflow solutions spanning image acquisition to treatment planning at ESTRO 2018

New Business Models and Cloud Innovation will Bring Growth Opportunities in Asia-Pacific Video Collaboration Market, finds Frost & Sullivan